RevolutionLogo.png
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
May 03, 2021 07:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
researchdrivelogo.jpg
Global Antiviral Therapies Market Expected to Surpass to $66,016.5 Million and Exhibit a CAGR of 3.1% from 2020 to 2027 - Exclusive Report [Pages - 208] by Research Dive
April 12, 2021 09:15 ET | Research Dive
New York, USA , April 12, 2021 (GLOBE NEWSWIRE) -- Research Dive in its latest published report estimates that the global antiviral therapies market will generate $66,016.5 million and exhibit...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Inducement Grants for New Staff
April 06, 2021 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Strengthens Business Development Team to Drive Customer Growth and Diversification
April 05, 2021 07:00 ET | Recro Pharma, Inc.
Six Recent Hires Provide Broader Coverage and Expanded Capabilities in the Areas of Sales and Marketing Significant Traction Already Achieved in First Months of 2021 MALVERN, Pa., April 05, 2021 ...
logo.jpg
Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
March 22, 2021 09:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
ARC logo.png
Antibiotics Market Value Expected To Reach US$ 57.1 Billion By 2027: Acumen Research and Consulting
March 18, 2021 10:05 ET | Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Antibiotics Market–Global Industry Analysis, Market Size, Opportunities and...
retro.jpg
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
March 17, 2021 07:00 ET | Retrotope
LOS ALTOS, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit 
March 11, 2021 07:05 ET | Annovis Bio, Inc.
BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Present at H.C. Wainwright Global Life Science Conference
March 02, 2021 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Fourth Quarter and Year End 2020 Financial Results
February 26, 2021 07:00 ET | Recro Pharma, Inc.
Strengthened Industry-Centric Leadership Reorganization Initiated to Enhance Operations as Recro Expands Customer Portfolio, Explores Inorganic Growth Opportunities Core Commercial Product Outlook...